As of March 2023, more than 300,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 750,000 patient years1
>9,800 patients in clinical trials and open-label extension
>300,000 patients with post-marketing experience
As of March 2023, more than 300,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 750,000 patient years1
>9,800 patients in clinical trials and open-label extension
>300,000 patients with post-marketing experience
References
1. Roche data on file: 31 March 2023, post-marketing experience; 31 March 2023, clinical trials data cut-off